Industry News
Pharmaceutical Industry News
Regeneron is having difficulties…
Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while another application for its
As Moderna plows ahead with its…
As Moderna plows ahead with its multiyear cost-savings scheme, the mRNA specialist delivered a better second quarter than expected, despite sales of its vaccines still leaving something to be desired.
Lenz Therapeutics has earned the…
Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past efforts by other drug developers have mostly been unsuccessful.
In honor of the annual World Lung…
In honor of the annual World Lung Cancer Day commemoration on Aug. 1, Johnson & Johnson has unveiled a new initiative encouraging patients to speak up in the treatment decision-making process.
In a new episode of Health…
In a new episode of Health Matters, Dr. Paul Offit shares how empathy, science and better communication can help restore confidence in vaccines.
A stellar launch of Amvuttra in…
A stellar launch of Amvuttra in the rare heart disease ATTR-CM has boosted Alnylam’s market cap above $50 billion.
Merz Aesthetics has revamped its…
Merz Aesthetics has revamped its sales and marketing leadership, promoting an employee and hiring a vice president from GSK to fill key positions.
Trump Demands That Drugmakers Lower Some of Their U.S. Prices by September
The administration has not put forward a clear legal authority to compel drugmakers to reduce their prices.
GSK signed a 12-asset licensing…
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is nearing the purchase of a large U.S. facility to help mitigate the impact of tariffs. And
The latest move by President…
The latest move by President Donald Trump to try to implement so-called “Most Favored Nation” drug pricing may be more bark than bite, one group of analysts contends.
Merck will reduce its workforce by…
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey drugmaker told Fierce Pharma. Word of the dismissals comes two days after Merck revealed a sweeping
In what has become a trend among…
In what has become a trend among European drugmakers presenting second-quarter earnings this week, the leadership at France’s Sanofi says it has little to be concerned about after a 15% tariff on European pharmaceutical shipments
A year after debuting the “Rare…
A year after debuting the “Rare Connections” series with a short film about patients’ experiences with neuromyelitis optica spectrum disorder, AstraZeneca’s rare disease unit is turning the cameras on generalized myasthenia gravis.
Applications are now open for a…
Applications are now open for a pilot program swapping out 340B providers' upfront discounts for equivalent post-purchase payments, an approach drugmakers say will reduce duplicate discounts and improve transparency.
The company’s 7% quarterly sales…
The company's 7% quarterly sales growth prompted an updated full-year sales outlook to flat, up from a previously expected slight decline.
On a day when AbbVie revealed…
On a day when AbbVie revealed booming sales of Skyrizi and Rinvoq and another positive adjustment to its 2025 guidance, the company also is reportedly angling to bolster its long-term prospects by way of an
Bristol Myers Squibb had a strong…
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s expectations. But CEO Chris Boerner still decided to address the company’s recent
The announcement of a 15% tariff…
The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the EU may have not been the ideal backdrop for the busiest week of European pharma earnings this quarter, but CEOs appeared
Moderna is taking its downsizing…
Moderna is taking its downsizing scheme a step further with plans to shrink its global workforce by around 10%. By the end of the year, the company expects to employ “fewer than 5,000 colleagues,” CEO
Evotec has inked a deal to sell…
Evotec has inked a deal to sell its biosimilars manufacturing facility in Toulouse, France to generics giant Sandoz for roughly $300 million. The transaction advances Evotec's plan to forge an "asset-lighter and capital-efficient" model for